Bookmark and Share

(IMMB) Enters into Agreement to Market Potential Ebola Virus Treatment

Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company’s ITV-1 Infectious Diseases Treatment in Africa

Company Begins Research of Potential EVD Application of the Patented Proteins

Monrovia, California (FSCwire) – Immunotech Laboratories, Inc. (OTC PINK: IMMB) (“Immunotech” or the “Company”) and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company’s HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa

With the establishment of an African operation, Immunotech hopes to fulfill the Company’s vision of bringing a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed by Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C and a new potential initiative, the Ebola virus.  In parts of Africa, approved experimental treatments are permitted, and with the Ebola outbreak, Immunotech expects that it can market its treatment for infectious diseases through the Company’s new agreement with Uldic.

ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is promising in combination with protease inhibitors in the treatment of the HIV/AIDS virus.  IPF is a platform technology that can be used to facilitate a broad range of applications.  It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today.  IPF has not shown itself to be subject to viral resistance, and it is cost effective.


The Company says that the immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens.  CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.

Immunotech has isolated IPF which is the most extensively studied CD 56 ligand to date.  The compounds has their ability to stimulate human NKT-cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor.  A lead compound, IPF, emerged from these studies and this protein exhibits a stronger adjuvant effect in various HIV vaccine platforms in mice.  IPF also provides a protective adjuvant effect with a candidate HIV and HCV vaccine.

While the majority of the Company’s studies have focused on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat infectious diseases.


About Immunotech Laboratories, Inc.

Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company strives to become a leader in immuno-therapeutic treatment and the prevention of HIV/AIDS, Cancer and other immuno-related disorders.

For more information visit:

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.


Billy Ray: 770-910-5380

Immunotech Laboratories, Inc.

Phone: 818-409-8988


Tuesday, October 21st, 2014 Uncategorized